News

July 15, 2022

Henry Wilson, PhD

Henry joined Auron in June 2022 as a computational biologist. Prior to Auron, Henry was a Principal Scientist of molecular discovery at BioMedicine Design Pfizer in Cambridge MA, where he supported antibody drug discovery and optimization across multiple portfolio programs. He played an active role in developing experimental and bioinformatic methods to profile antibody repertoires…

May 20, 2022

Kimberly Straley

Kim Straley joined Auron Therapeutics in March of 2021. Kim has 20 years of industry experience in cell biology small molecule drug discovery from her time at Vertex Pharmaceuticals and Agios Pharmaceuticals. Her career has focused on developing cell-based assays for SAR exploration as well as detailed mechanistic studies, both of which significantly contributed to…

May 20, 2022

Peter Slivka, PhD

Dr. Slivka joined Auron Therapeutics in April 2022 as Director, Translational Biology. Prior to joining Auron, he was a Principal Scientist at AbbVie, Inc. in the department of Immunology Early Discovery with a focus on dermatological diseases. During his time at AbbVie, Dr. Slivka led and supported many efforts throughout various stages of drug discovery….

May 20, 2022

James Neef

James joined Auron in February 2022 as Director of Chemistry. Prior to joining Auron, James worked in the global discovery chemistry group within Novartis Institutes for BioMedical Research (NIBR). James has supported multiple disease areas throughout his tenure at Novartis, most recently supporting the Neuroscience disease area where he was project leader for a program…

May 20, 2022

Andrew McRiner, PhD

Dr. McRiner joined Auron Therapeutics in December 2020 as VP, Head of Drug Discovery. Most recently he was Director and Head of Medicinal Chemistry at X-Chem Pharmaceuticals, building drug discovery capabilities on top of a highly efficient DNA-Encoded Library (DEL) Screening platform. Dr. McRiner was a founding member of a 25-member team developing a portfolio…

May 20, 2022

Joe DeBartolo, PhD

Dr. DeBartolo joined Auron Therapeutics in June 2021 as Associate Director, Computational Biology. Most recently he was Senior Principal Scientist of Bioinformatics at BioMedicine Design Pfizer in Cambridge MA where he built database-linked applications and visual analysis tools for NGS platforms, including single-cell RNA-seq and DNA Ig-Seq. A big part of this work involved designing…

May 20, 2022

Betty Chan, PhD

Betty joined Auron Therapeutics in January 2021.  She is a data-driven and motivated scientist with 15+ years of experience building and leading biochemistry capabilities.  Betty’s interest and expertise include advancing small molecules from various hit finding approaches (including DNA-encoded library screening and machine learning) to IND filing and developing innovative assays to interrogate new modalities…

May 20, 2022

Laura Antipov, PhD

Laura Antipov is a self-proclaimed “start-up junkie” with a passion for taking big ideas and translating them into clear, actionable plans. She has been in the biotech industry for 10 years, at three different early stage start-ups, always playing the same role: a “Jack-of-all-trades” problem solver. Laura joined Auron in January 2019; prior to that,…